FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: A report of 9 cases

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Pisani, Francesco ^a   Maini, Carlo Ludovico ^a   Sciuto, Rosa ^a   Dessanti, Laura ^a   D'Andrea, Mariella ^a   Assisi, Daniela ^a   Petti, Maria Concetta ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; FLUORODEOXYGLUCOSE; IBRITUMOMAB TIUXETAN; ITRACONAZOLE; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VALACICLOVIR; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE; YTTRIUM;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER GRADING; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONIDIOBOLOMYCOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; HERPES ZOSTER; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; CANCER STAGING; FEASIBILITY STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDIES; VIDARABINE; YTTRIUM RADIOISOTOPES;

EID: 79551689814     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-16     Document Type: Article

References (14)

1. Fludarabine, Cyclophosphamide, and Rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin's lymphoma. CS Tam M Wolf HM Prince EH Januszewicz D Westerman IK Lin D Carney JF Seymour, (Pubitemid 43791961)
2. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. MS Czuczman A Koryzna A Mohr C Stewart K Danohue L Blumenson ZP Bemstein P McCarthy A Alam F Hernandez-Ilizaliturri M Skipper K Brown A Chanan-Khan D Klippestein P Loud MK Rock M Benyunes A Grillo-Lopez SH Bemstein, J Clin Oncol 2005 23 694 704 10.1200/JCO.2005.02.172 15681517 (Pubitemid 46224168)
3. Phase III trial of consolidation therapy with Yttrium-90-Ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. F Morschhauser J Radford A Van Hoof U Vitolo P Soubeyran H Tilly PL Huijgens A Kolstad F d'Amore MG Diaz M Petrini C Sebban PL Zinzani MHJ van Oers W van Putten A Bischof-Delaloye A Rohatiner G Salles J Kuhlmann A Hagenbeek, J Clin Oncol 2008 26 5156 5164 10.1200/JCO.2008.17.2015 18854568
4. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: A review of the evidence. F Morschhauser M Dreyling A Rohatiner F Hagemeister A Bischof-Delaloye, The Oncologist 2009 14 17 29 10.1634/theoncologist.2009-S2-17 19819921
5. Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. TE Witzing CA White LI Gordon GA Wiseman C Emmanouilides JL Murray J Lister PS Multani, J Clin Oncol 2003 21 1263 1270 10.1200/JCO.2003.08.043 12663713 (Pubitemid 46606402)
6. Treatment with Yttrium-90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. C Emmanouilides TE Witzing LI Gordon K Vo GA Wiseman IW Flinn M Darif RJ Schilder A Molina, Leuk Lymphoma 2006 47 629 636 10.1080/10428190500376076 16690521
7. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin's lymphoma treated with Yttrium-90 ibritumomab tiuxetan. TE Witzing A Molina LI Gordon C Emmanouilides RJ Schilder IW Flinn M Darif R Macklis K Vo GA Wiseman, Cancer 2007 109 1804 1810 10.1002/cncr.22617 17380530 (Pubitemid 46668544)
8. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I-131-tositumomab for untreated follicular lymphoma. JP Leonard M Coleman L Kostakoglu A Chadbum E Cesarman RR Furman MW Schuster R Niesvizky D Muss J Fiore S Kroll G Tidmarsh S Vallabhajosula SJ Goldsmith, J Clin Oncol 2005 23 5696 5704 10.1200/JCO.2005.14.803 16110029
9. Phase II trial of CHOP chemotherapy followed by I-131-tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five years follow up of Southwest Oncology Group Protocol 59911. OW Press JM Unger RM Braziel DG Maloney TP Miller M Leblanc RI Fisher, J Clin Oncol 2006 24 4143 4129 10.1200/JCO.2006.05.8198 16896003
10. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. S Sacchi S Pozzi R Marcheselli M Federico A Tucci F Merli L Orsucci M Liberati D Vallisa M Brugiatelli, Cancer 2007 110 121 128 10.1002/cncr.22740 17503433 (Pubitemid 46992032)
11. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma - Role of radioimmunotherapy. M Dreyling L Trumper C von Schilling M Rummel U Holtkamp A Waldmann J Wehmeyer M Freund, Ann Hematol 2007 86 81 87 10.1007/s00277-006-0207-0 17068667 (Pubitemid 44963998)
12. Consensus conference: Implementing treatment recommendations on Yttrium-90 immunotherapy in clinical practice - Report of a European workshop. PL Zinzani F d'Amore E Bombardieri E Brammer JG Codina T Ilidge W Jurczak W Linkesch F Morschhauser E Vandenberghe A Van Hoof, Eur J Cancer 2008 44 366 373 10.1016/j.ejca.2007.12.008 18194857
13. Treatment-related myelodysplastic syndrome and acute myelogenous leukaemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. MS Czuczman C Emmanoulides M Darif TE Witzig LI Gordon S Revell K Vo A Molina, J Clin Oncol 2007 25 4285 4292 10.1200/JCO.2006.09.2882 17709799 (Pubitemid 47548569)
14. FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y-90: multicentric study. E Lopci I Santi E Derenzini C Fonti G Savelli F Bertagna M Bell M Botto D Huglo F Morschhauser PL Zinzani S Fanti, Ann Oncol 2010 21 1877 1883 10.1093/annonc/mdq024 20147744